General Information of Drug (ID: DMCFPBE)

Drug Name
NN8765 Drug Info
Indication
Disease Entry ICD 11 Status REF
Rheumatoid arthritis FA20 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMCFPBE

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Preclinical Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Monalizumab DMG7XHE Chronic lymphocytic leukaemia 2A82.0 Phase 1/2 [3]
BMS-986315 DMTEY1L Solid tumour/cancer 2A00-2F9Z Phase 1/2 [4]
IM1240 DMTV0DK Aggressive cancer 2A00-2F9Z Preclinical [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
NKG2-A/B-activating NK receptor (NKG2A) TTC4IMS NKG2A_HUMAN Modulator [2]

References

1 Clinical pipeline report, company report or official report of Innate Pharma.
2 Handbook of Therapeutic Antibodies. 2014. 1. Page(1098).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT04349267) Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
5 Clinical pipeline report, company report or official report of Purple